Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 PUFAs for aGVHD Prevention in Allo-HSCT
NCT07162688Phase 2Enrolling by invitation
- Sponsor
- Fujian Medical University
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of omega-3 fatty acid in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Fujian Medical University. Primary endpoint: Incidence and Severity of Acute Graft-versus-Host Disease at 100 days. Started May 2025; status: enrolling by invitation.
02
Drugs
omega-3 fatty acid
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07162688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162688.